King Pharmaceuticals KG Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$7.43M— | —— | -$5.05M-107% | $69.93M+17,848% | -$394K— | ||
| $9K-97.0% | $299K+111% | -$2.82M-201% | $2.78M+15,339% | $18K-76.9% | ||
| $1.45M— | —— | —— | —— | $15K— | ||
| $5.56M+111% | -$50.55M-316% | $23.36M+169% | $8.7M+3,650% | -$245K+37.6% | ||
| -$139K-117% | $810K+30.9% | $619K— | —— | $270K+174% | ||
| $1.34M+231% | $405K-92.6% | $5.49M+419% | $1.06M— | $0— | ||
| -$512K+76.8% | -$2.21M+25.9% | -$2.98M-125% | -$1.33M— | $0— | ||
| -$16.74M-138% | -$7.04M+68.2% | -$22.16M+11.7% | -$25.09M— | $0— | ||
| -$15.13M+77.0% | -$65.71M-578% | -$9.7M+51.2% | -$19.86M-2,167% | -$876K-307% | ||
| $2.26M+9.0% | $2.07M-65.9% | $6.08M+340% | $1.38M— | $0— | ||
| $38.12M-19.9% | $47.6M+504% | $7.88M+7.7% | $7.31M— | $0— | ||
| $7K+133% | $3K-82.4% | $17K+1,600% | $1K— | $0— | ||
| $474K+0.6% | $471K+313% | $114K-76.7% | $490K— | $0— | ||
| -$9.48M+39.6% | -$15.68M— | —— | —— | $0— | ||
| $53M+24.6% | $42.53M+165% | $16.08M-81.8% | $88.33M— | $0— | ||
| $486K— | —— | —— | —— | $0— | ||
| -$486K— | —— | —— | -$40M— | $0— | ||
| -$548K— | —— | —— | $661K— | $0— | ||
| $36.83M— | —— | $6.22M-78.7% | $29.13M+3,426% | -$876K-307% | ||
| —— | -$703.25K0.0% | -$703.25K0.0% | -$703.25K0.0% | -$703.25K— | ||
| —— | $2.83M0.0% | $2.83M0.0% | $2.83M0.0% | $2.83M— | ||
| —— | $12K0.0% | $12K0.0% | $12K0.0% | $12K— | ||
| -$681K+33.0% | -$1.02M-35.8% | -$748K+36.9% | -$1.19M— | $0— | ||
| $2.23M— | —— | $2.85M— | —— | $0— | ||
| $1.34M+231% | $405K-92.6% | $5.49M+419% | $1.06M— | $0— | ||
| —— | -$703.25K0.0% | -$703.25K0.0% | -$703.25K0.0% | -$703.25K— | ||
| -$1K-102% | $48K+300% | -$24K— | $0— | $0— | ||
| -$123K— | —— | $144K-82.0% | $801K— | $0— | ||
| $5.56M+111% | -$50.55M-316% | $23.36M+169% | $8.7M+3,650% | -$245K+37.6% | ||
| -$16.74M-138% | -$7.04M+68.2% | -$22.16M+11.7% | -$25.09M— | $0— | ||
| -$139K-117% | $810K+30.9% | $619K— | —— | $270K+174% | ||
| -$373K+95.9% | -$9.18M-1,341% | -$637K-585% | -$93K— | $0— | ||
| -$2.65M— | —— | -$8.95M-350% | $3.59M— | $0— | ||
| -$512K+76.8% | -$2.21M+25.9% | -$2.98M-125% | -$1.33M— | $0— | ||
| -$9.48M+39.6% | -$15.68M— | —— | —— | $0— | ||
| $7K+133% | $3K-82.4% | $17K+1,600% | $1K— | $0— | ||
| $474K+0.6% | $471K+313% | $114K-76.7% | $490K— | $0— | ||
| $2.26M+9.0% | $2.07M-65.9% | $6.08M+340% | $1.38M— | $0— | ||
| $44.27M— | —— | —— | —— | $0— | ||
| $38.12M-19.9% | $47.6M+504% | $7.88M+7.7% | $7.31M— | $0— | ||
| -$3.02M— | —— | $563K-15.7% | $668K— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does King Pharmaceuticals generate?
- King Pharmaceuticals (KG) generated -$110.4M in operating cash flow over the trailing twelve months.
- Where does King Pharmaceuticals's cash flow data come from?
- Every line is extracted from King Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
